THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action you should take, you should seek your own personal financial advice from your stockbroker, bank manager, solicitor, accountant, or other financial adviser authorised under the Financial Services and Markets Act 2000.

If you have sold or otherwise transferred all your ValiRX plc shares, please send this document, together with the accompanying documents, as soon as possible to the purchaser or transferee, or to the stockbroker, bank or other agent through whom the sale or transfer was effected, for delivery to the purchaser or transferee.

VALIRX PLC
(incorporated and registered in England and Wales under company registration number 03916791)

NOTICE OF ANNUAL GENERAL MEETING

Notice of the Annual General Meeting of ValiRX plc to be held at 10.00am on 29 May 2012 at the offices of Nabarro LLP, Lacon House, 84 Theobald’s Road, London WC1X 8RW is set out at the end of this document.

A Form of Proxy for use at the Annual General Meeting is enclosed. To be valid, the Form of Proxy should be completed, signed and returned in accordance with the instructions printed on it to Capita Registrars at PXS, The Registry, 34 Beckenham Road, Beckenham BR3 4TU as soon as possible but in any event so as to arrive no later than 10.00am on 27 May 2012.
Dear shareholder

I am pleased to be writing to you with details of our Annual General Meeting (AGM) which we are holding at 10.00am on 29 May 2012 at the offices of Nabarro LLP, Lacon House, 84 Theobald’s Road, London WC1X 8RW. The formal notice of AGM is set out on page 3 of this document.

If you would like to vote on the resolutions but cannot come to the AGM, you can appoint a proxy to exercise all or any of your rights to attend, vote and speak at the AGM by using one of the methods set out in the notes to the notice of AGM. Appointing a proxy will not prevent you from attending and voting in person at the AGM.

The purpose of this letter is to explain certain elements of the business to be considered at the meeting.

If you have a question you wish to ask at the AGM it would assist us if you would either write to the Company Secretary at ValiRX plc, 24 Greville Street, London EC1N 8SS or e-mail info@valirx.com. I will deal with the issues most frequently raised at the meeting.

Resolutions

Resolution 1 – to receive the annual report and accounts

The Chairman will present the annual report and accounts for the year ended 31 December 2011 to the meeting. These accounts will be available on the Company’s website at www.valirx.com from today’s date.

However, shareholders who have elected not to receive electronic communications will also find a copy of these accounts enclosed with this document.

Resolutions 2 and 3 – re-appointment of Directors

Resolutions 2 and 3 deal with the re-appointment of certain of the Directors. The Board of Directors of the Company (“Board”) has confirmed, following a performance review, that all Directors standing for re-appointment continue to perform effectively and demonstrate commitment to their role.

Summary biographical details of those seeking re-election are set out below:

George Morris, Chief Operations Officer
George was appointed to the Board in October 2006. George has over 25 years’ experience in biological and medical research and financial services. In the past he has worked for Guy’s Hospital Medical School Department of Medicine, King’s College and University College London. As a research scientist, he is an author of numerous books and articles on refereed papers, approximately 70 abstracts, short reports and posters, and an inventor of multiple patents.

Oliver de Giorgio-Miller, Non-executive Director
Oliver was appointed to the Board in May 2011. Oliver has a wealth of experience in the management and commercial advancement of life science companies. He has worked for over 30 years with several global pharmaceutical and medical device companies including Schering AG, Hoffman la Roche, Intavent-Orthofix and Photo Therapeutics, a Cancer Research UK company, and he has extensive experience advising a number of other early stage biopharmaceutical and medical device companies.

Resolutions 4 and 5 – re-appointment of auditors

Resolution 4 relates to the re-appointment of Adler Shine LLP as the Company’s auditors to hold office until the next AGM of the Company and Resolution 5 authorises the Directors to set their remuneration. The Directors have delegated the responsibility of setting the auditors’ remuneration to the Audit Committee of the Board.

Resolution 6 – allotment of share capital

At the last AGM of the Company held on 23 June 2011, the Directors were given authority to allot ordinary shares in the capital of the Company up to a maximum nominal amount of three hundred and forty eight thousand one hundred and eighty seven pounds (£348,187), representing approximately one-third of the Company’s then issued ordinary share capital.

Your Board considers it appropriate that a larger authority be granted to allot ordinary shares up to a maximum nominal amount of six hundred and twenty nine thousand seven hundred and eighty one pounds (£629,781), representing approximately 50% of the Company’s issued ordinary share capital as at 4 May 2012 (the latest practicable date before publication of this letter) during the period up to the conclusion of the next AGM in 2013.

As at the date of this letter, the Company does not hold any optional shares in the capital of the Company in treasury.

Resolution 7 - disapplication of statutory pre-emption rights

Resolution 7 will empower the Directors to allot ordinary shares in the capital of the Company for cash on a non-pre-emptive basis:

1. in connection with a rights issue or other pro-rata offer to existing shareholders; and

2. (other than in connection with a rights issue) up to a maximum nominal value of two hundred and fifty one thousand nine hundred and twelve pounds (£251,912), representing approximately 20% of the issued ordinary share capital of the Company as at 4 May 2012 (the latest practicable date before publication of this letter).

Your Board considers it appropriate to seek the levels of authority sought under Resolutions 6 and 7 in order to give the Directors flexibility as the Company moves to the next stage of its development. However, the Board has no present intention of exercising either of these authorities.

Recommendation

The Board considers that the resolutions to be proposed at the AGM (the “Resolutions”) will promote the success of the Company and are in the best interests of the Company and its shareholders as a whole. The Directors unanimously recommend that you vote in favour of the Resolutions as they intend to do in respect of their own beneficial holdings which amount in aggregate to 55,110,731 shares representing approximately 4.4% of the existing issued ordinary share capital of the Company.

Yours sincerely

Nicholas Thorniley
Chairman
NOTICE OF ANNUAL GENERAL MEETING
ValiRX plc

Notice is hereby given that the Annual General Meeting of ValiRX plc (the “Company”) will be held at the offices of Nabarro LLP, Lacon House, 84 Theobald’s Road, London WC1X 8RW on 29 May 2012 at 10.00am to transact the following business. Resolutions 1 to 6 inclusive will be proposed as ordinary resolutions. Resolution 7 will be proposed as a special resolution:

1. To receive the report of the Directors, the accounts and the auditors’ report on the accounts and on the auditable part of the Directors’ Remuneration Report for the period ended 31 December 2011.

2. To re-elect George Morris as a Director of the Company.

3. To re-elect Oliver de Giorgio-Miller as a Director of the Company.

4. To re-appoint Adler Shine LLP as auditors to the Company, to hold office until the conclusion of the next general meeting at which accounts are laid before the Company.

5. To authorise the Directors to determine the auditors’ remuneration.

6. That the Directors be and they are hereby generally and unconditionally authorised in accordance with Section 551 of the Companies Act 2006 (the “2006 Act”) in substitution for all existing authorities to exercise all the powers of the Company to allot shares and to make offers or agreements to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (together “Relevant Securities”) up to an aggregate nominal amount of six hundred and twenty nine thousand seven hundred and eighty one pounds (£629,781), provided that this authority shall expire at the conclusion of the next Annual General Meeting of the Company after the passing of this resolution or, if earlier, on the date that is 15 months after the date of the Annual General Meeting, except that the Company may before such expiry make an offer or agreement that would or might require Relevant Securities or equity securities as the case may be to be allotted after such expiry and the Directors may allot Relevant Securities or equity securities in pursuance of any such offer or agreement as if the authority in question had not expired.

7. That the Directors be and are empowered, in accordance with Section 570 of the 2006 Act, to allot equity securities (as defined in Section 560(1) of the 2006 Act) for cash pursuant to the authority conferred by Resolution 6 or by way of a sale of treasury shares as if Section 561(1) of the 2006 Act did not apply to any such allotment, provided that this power shall be limited to:

7.1 the allotment of equity securities in connection with a rights issue or other pro-rata offer in favour of holders of ordinary shares where the equity securities respectively attributable to the interests of all those persons at such record date as the Directors may determine are proportionate (as nearly as may be) to the respective numbers of equity securities held or deemed to be held by them or are otherwise allotted in accordance with the rights attaching to such equity securities subject in each case to such exclusions or other arrangements as the Directors may consider necessary or expedient to deal with fractional entitlements or legal difficulties under the laws of any territory or the requirements of a regulatory body or stock exchange or by virtue of shares being represented by depositary receipts or any other matter whatsoever; and

7.2 the allotment (otherwise than pursuant to paragraph 7.1 above) of equity securities up to an aggregate nominal amount of two hundred and fifty one thousand nine hundred and twelve pounds (£251,912), and shall expire upon the expiry of the general authority conferred by Resolution 6 above, except that the Company may make an offer or agreement before this power expires that would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of such offer or agreement as if the power conferred by this resolution had not expired.

By order of the Board

Kevin Alexander
Secretary
4 May 2012

Registered office
24 Greville Street
London EC1N 8SS
NOTICE OF ANNUAL GENERAL MEETING CONTINUED

ValiRX plc

Notes
1. A member entitled to attend and vote at the meeting is entitled to appoint another person(s) (who need not be a member of the Company) to exercise all or any of his rights to attend, speak and vote at the meeting. A member can appoint more than one proxy in relation to the meeting, provided that each proxy is appointed to exercise the rights attaching to different shares held by him.

2. Your proxy could be the Chairman, another Director of the Company or another person who has agreed to attend to represent you. Your proxy will vote as you instruct and must attend the meeting for your vote to be counted. Details of how to appoint the Chairman or another person as your proxy using the proxy form are set out in the notes to the proxy form. Appointing a proxy does not preclude you from attending the meeting and voting in person. If you attend the meeting in person, your proxy appointment will automatically be terminated.

3. An appointment of proxy is provided with this Notice and instructions for use are shown on the form. In order to be valid, a completed appointment of proxy must be returned to the Company by one of the following methods:

   3.1 in hard copy form by post, by courier or by hand to the Company’s registrars, Capita Registrars, at the address shown on the form of proxy; or

   3.2 in the case of CREST members, by using the CREST electronic proxy appointment service in accordance with the procedures set out below, and in each case must be received by the Company not less than 48 hours before the time fixed for the meeting.

   Please note that any electronic communication sent to us or our registrars in respect of the appointment of a proxy that is found to contain a computer virus will not be accepted.

4. To change your proxy instructions you may return a new proxy appointment using the methods set out above. Where you have appointed a proxy using the hard copy proxy form and would like to change the instructions using another hard copy proxy form, please contact Capita Registrars at PXS, The Registry, 34 Beckenham Road, Beckenham BR3 4TU. The deadline for receipt of proxy appointments (see above) also applies in relation to amended instructions. Any attempt to terminate or amend a proxy appointment received after the relevant deadline will be disregarded. Where two or more valid separate appointments of proxy are received in respect of the same share in respect of the same meeting, the one which is last sent shall be treated as replacing and revoking the other or others.

5.1 CREST members who wish to appoint a proxy or proxies by using the CREST electronic proxy appointment service may do so by using the procedures described in the CREST Manual. CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

5. In order for a proxy appointment made by means of CREST to be valid, the appropriate CREST message (a “CREST Proxy Instruction”) must be properly authenticated in accordance with Euroclear UK & Ireland’s specifications and must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the issuer’s agent, Capita Registrars (ID RA10) by the latest time(s) for receipt of proxy appointments specified in the notice of meeting. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer’s agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

5.3 The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

5.4 CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & Ireland does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

6. Only those shareholders registered in the Register of Members of the Company as at 6.00pm on 27 May 2012 (or, if the meeting is adjourned, on the date that is two days before the time of the adjourned meeting) shall be entitled to attend and vote at the meeting or adjourned meeting in respect of the number of shares registered in their respective names at that time. Changes to the Register of Members after that time will be disregarded in determining the rights of any person to attend or vote at the meeting or adjourned meeting.

7. Any corporation that is a member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that they do not do so in relation to the same shares.

8. You may not use any electronic address provided either in this Notice of Annual General Meeting or any related documents (including the form of proxy) to communicate with the Company for any purposes other than those expressly stated.

9. As at [1] May 2012 (being the last business day before the publication of this Notice), the Company’s issued share capital consisted of 1,259,562,609 ordinary shares carrying one vote each. The Company does not hold any shares in treasury.

10. Any member attending the meeting has the right to ask questions. The Company must cause to be answered any such question relating to the business being dealt with at the meeting but no such answer need be given if:

10.1 to do so would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information;

10.2 the answer has already been given on a website in the form of an answer to a question; or

10.3 it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.

11. The following documents are available for inspection at the registered office of the Company during normal business hours on each weekday (public holidays excluded) and at the place of the Annual General Meeting for 15 minutes prior to and during the meeting:

11.1 copies of the Executive Directors’ service contracts with the Company; and

11.2 copies of the letters of appointment of Non-executive Directors.